• In late April 2026, Merck reported stronger-than-expected first-quarter results, raised its full-year revenue and earnings guidance, and secured FDA approval for IDVYNSO, a complete two-drug HIV-1 regimen for virologically suppressed adults.
• Together with advancing oncology programs such as KEYTRUDA-based regimens and WELIREG in renal cell carcinoma, these developments reinforce Merck’s efforts to broaden growth drivers ahead of expected pressure on legacy products.
• We’ll now examine how this earnings beat and upgraded outlook, underpinned by oncology and new launches, affects Merck’s existing investment narrative.

Uncover the next big thing with 24 elite penny stocks that balance risk and reward.

Merck Investment Narrative Recap

To own Merck today, you need to believe its expanding oncology, cardiometabolic, and infectious disease portfolio can gradually lessen reliance on KEYTRUDA before its loss of exclusivity, while managing pricing and regulatory pressures. The Q1 2026 beat and higher guidance, powered by oncology and new launches, support this near term growth driver. They do not materially change the biggest risk, which remains how Merck replaces eventual KEYTRUDA and GARDASIL pressure over time.

Among the recent updates, the FDA’s approval of IDVYNSO, a complete two drug HIV regimen for virologically suppressed adults, is particularly relevant. It adds another non oncology pillar alongside WINREVAIR and CAPVAXIVE, reinforcing the idea that Merck’s future is meant to rest on multiple growth drivers rather than a single blockbuster, which is central to how investors think about the KEYTRUDA patent overhang.

Yet beneath these gains, investors should be aware of how pricing pressure and the eventual KEYTRUDA loss of exclusivity could...

Merck's narrative projects $72.0 billion revenue and $24.3 billion earnings by 2028.

Uncover how Merck's forecasts yield a $124.88 fair value, a 11% upside to its current price.

Exploring Other Perspectives

Some of the lowest ranked analysts were much more cautious before this news, assuming revenue of about US$71.3 billion and earnings of roughly US$20.4 billion by 2029, and you can see how their concern about pricing pressure alongside reliance on KEYTRUDA contrasts with a more optimistic take that emphasizes the broadening pipeline and might now be revisited in light of Merck’s latest approvals and guidance.

Explore 13 other fair value estimates on Merck - why the stock might be worth 10% less than the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Merck research is our analysis highlighting 2 key rewards and 4 important warning signs that could impact your investment decision.
• Our free Merck research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Merck's overall financial health at a glance.

Contemplating Other Strategies?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• AI is about to change healthcare. These 33 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 31 best rare earth metal stocks of the very few that mine this essential strategic resource.
• Find 51 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.